Real world evidence and these things people are citing is just hand waving and conjecture at this point. Basket trials are what NWBO needs to run, but they don't have the resources. I mean 1B + shares for a non-revenue bio is unheard of. If you want to run these trials or go at at it alone, dilution hell is forthcoming and we will easily see 2B+ shares. Better off letting BP run these trials and handle the other RAs. I'm okay with getting UK MHRA done even if they move at a snails pace. But the rest of it is better off in more capable hands.
Market Data 
Markets 
AI
